Patient flow and disease assessments before and after addition of IMiDs to daratumumab. (A) Patient flow and response monitoring of the daratumumab/IMiD/dexamethasone combination. (B-D) Each line represents an individual patient’s serum M-protein (B), urine M-protein (C), and involved free light chain (D) values. FLC, free light chain; PD, progressive disease.